Skip to main content

Perrigo Company(PRGO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE

PR Newswire - Mon Sep 12, 2022

DUBLIN, Sept. 12, 2022 /PRNewswire/ -- Perrigo Company plc ( NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) on November 18, 2022, to review the Company's application for Opill® daily oral contraceptive for OTC use.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.